An Inhaler For Electronically Supervised Parenteral Administration of a Pharmaceutical Composition

Abstract

An inhaler (400) for electronically supervised parenteral administration of a dry powder pharmaceutical composition comprising: storage means (410) for the pharmaceutical composition in a form of a dry powder; administration means (411) for ad- ministration of the pharmaceutical composition; memory (404) and processing means (402); communication means (401); controlled blocking means (403) for blocking administration of the pharmaceutical composition, wherein the inhaler (400) is adapted to receive data corresponding to an administration scheme (11), to determine whether a mobile device (300) with an authorisation token assigned thereto is present, and to control the controlled blocking means (403) so as to allow administration of the pharmaceutical composition only with compliance with the administration scheme (11) in the presence of the mobile device (300) with the authorisation token (12) assigned thereto.

Claims

1. An inhaler for electronically supervised parenteral administration of a dry powder pharmaceutical composition comprising: storage means for the pharmaceutical composition in a form of a dry powder, administration means for administration of the pharmaceutical composition; memory and processing means communication means; controlled blocking means for blocking administration of the pharmaceutical composition, wherein the inhaler is adapted to receive data corresponding to an administration scheme, to determine whether a mobile device with an authorisation token assigned thereto is present, and to control the controlled blocking means so as to allow administration of the pharmaceutical composition only with compliance with the administration scheme in the presence of the mobile device with the authorisation token reassigned thereto.

2. The inhaler according to claim 1 wherein the inhaler is further adapted to measure via sensor unit at least one physical property of the dry powder pharmaceutical composition administration process within the inhaler during an administration process and communicate the measured physical property to the mobile device.

3. The inhaler according to claim 2 wherein the physical property of the pharmaceutical composition administration process measured within the inhaler during an administration process is an air pressure, sound intensity, vibration magnitude or any combination of such physical properties.

4. The inhaler according to claim 2 wherein the sensor unit comprises a microphone, and the measured physical property is an amplitude of a sound wave.

5. The inhaler of claim 2 wherein the sensor is pllaced inside the mixing chamber where a dry powder pharmaceutical composition is mixed with air during the inhalation.

6. The inhaler according to claim 1 wherein the uncontrolled blocking means comprises a drive unit and active actuating clement that blocks the transfer of a dose of the dry powder pharmaceutical composition from the storage to the administration unit.

7. The inhaler according of claim 1 wherein actuating element in a blocking state blocks the transferor a dose of the pharmaceutical composition from the storage to the administration unit, and in an open position allows administration of the pharmaceutical composition in response to a control signal from the control unit.

8. The inhaler of claim 1 wherein, and upon receiving a control signal from the processing unit actuating element moves into an open state and allows administration of the pharmaceutical composition.

9.The inhaler according of claim 1 wherein the blocking means comprises an element selected from a group comprising: a valve, pin. bolt, relay, key. normally closed switch.

10. The inhaler according to claim 1 wherein a dry powder pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, by direct administration to the lungs via pulmonary route.

11. The inhaler according to claims 1 comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry powder pharmaceutical composition.

12. The inhaler of claim 10 wherein pharmaceutically acceptable salt is hydrochloride.

13. The inhaler of claim 10 wherein ketamine is esketamine hydrochloride.

14. The inhaler of claim 10 wherein the composition comprises from 2 mg to 100 mg of micronized ketamine calculated as a free base per nominal unit dose.

15. The inhaler according to claim 14 wherein composition comprises from 2 mg to 40 mg of micronized ketamine calculated as a free base per nominal unit dose.

16. The inhaler according to claim 15 wherein the composition comprises 4 mg of micronized esketamine calculated as a free base per nominal unit dose.

17. The inhaler of claim 10 wherein composition comprises one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 - 3% by weight, with respect to the total weight of the composition.

18. The inhaler of claim 10 wherein composition comprises ketamine having median particle diameter d50 of 1 - 10μm. d10 of 0.2 - 5μm and d90 of 3 - 35μm. as measured by laser diffraction technique.

19. The inhaler according of claim 14 adapted to provide emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.

20. The inhaler according to claim 19 wherein the fraction 5 of the emitted dose delivered to the lungs is at least 40%.

21. The inhaler of claim lO wherein the composition for administration via pulmonary route is comprised in a blister with plurality of individual nominal unit doses premetered and individually sealed.

22. The inhaler of claim 10 wherein the composition for administration via pulmonary route is comprised in a capsule with a single nominal unit dose.

23. The inhaler of claim 10 wherein the composition for administration via pulmonary route is comprised in a multi-dose powder reservoir.

24. The inhaler of claim 10 wherein the administration scheme provides a self-administration by a patient by inhalation of a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses, for example such as a sequence of at least 3 single doses, each single dose consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation.

25. The inhaler according to claim 24 wherein the administration scheme comprises the sequence of csketamine three single doses consisting of 3 or 4 puffs in a period of 30 minutes, single doses being separated by a break periods of 15 minutes, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.

26. A method for treatment of depression in a patient in need thereof, the method comprising self-administration of ketamine or its pharmaceutically acceptable salt by said patient by pulmonary route as dry powder inhalable pharmaceutical formulation via an inhaler in a remotely dictated and controlled manner in accordance with the administration scheme prescribed by the attending physician, in the presence of a patient's mobile device with the authorisation token assigned thereto, wherein said inhaler is operated in compliance with the administration scheme via a controlled blocking means adopted to allow administration of a pharmaceutical composition only with compliance with the administration scheme and in the presence of a patient's mobile device with the authorisation token assigned thereto.

27. The method of claim 26, wherein said administration scheme is set by the attending physician who generates a control signal comprising said prescribed self-administration scheme and an authorisation token assigned to the subject's mobile device using a control terminal.

28. The method of claim 26, wherein the control signal with the self-administration scheme is received by the inhaler in response to activation and registration of the authorisation token with the inhaler.

29. The method of claim 26, wherein said administration is allowed by the controlled blocking means only with compliance with the administration scheme.

30. The method of claim 26 wherein said administration is protected by the remotely controlled blocking means against misuse or abuse by the patient or a third person.

31. The method according to claim 26 wherein pharmaceutically acceptable salt is hydrochloride.

32. The method of claim 26 wherein ketamine is eskctamine hydrochloride.

33. The method of claim 26 wherein the composition comprises from 2 mg to 100 mg of micronized ketamine calculated as a free base per nominal unit dose.

34. The method according to claim 33 wherein composition comprises from 2 mg to 40 mg of micronized ketamine calculated as a free base per nominal unit dose.

35. The method according to claim 34 wherein the composition comprises 4 mg of micronized esketamine calculated as a free base per nominal unit dose.

36. The method of claim 26 wherein composition comprises one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 - 3% by weight, with respect to the total weight of the composition.

37. The method of claim 26 wherein composition comprises ketamine having median particle diameter d50 of 1 - 10 μm. d10 of 0.2 - 5 μm and d90 of 3 - 35 μm, as measured by laser diffraction technique.

38.The method of claim 34 adopted to provide emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.

39. The method according to claim 38 wherein the fraction 5 of the emitted dose delivered to the lungs is at least 40%.

40. The method of cIaim 26 wherein the composition for administration via pulmonary route is comprised in a blister with plurality of individual nominal unit doses premetered and individually sealed.

41. The method of claim 26 wherein the composition for administration via pulmonary route is comprised in a capsule with a single nominal unit dose.

42. The method of claim 26 wherein the composition for administration via pulmonary route is comprised in a multi-dose powder reservoir.

43. The method of claim 26 wherein the administration scheme provides a self-administration by a patient by inhalation of a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses, for example such as a sequence of at least 3 single doses, each single dose consisting of multiple puffs, such as 1,2, 3 or 4 puffs, preferably 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation.

44. The method according to claim 43 wherein the administration scheme comprises the sequence of esketamine three single doses consisting of 3 or 4 puffs in a period of 30 minutes, single doses being separated by a break periods of 15 minutes, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.

Description

[0049] Still further advantages, as well as features and ways of carrying out the present invention will become apparent from the following detailed description of a preferred embodiment, presented by way of a non- limiting example, making reference to the figures of the accompanying drawings, in which:

[0050] FIG. 1 presents NGI deposition data for the composition of Example 1;

[0051] FIG. 2 presents NGI deposition data for the composition of Example 2;

[0052] FIG. 3 presents NGI deposition data for the composition of Example 3;

[0053] FIG. 4 presents NGI deposition data for the composition of Example 4;

[0054] FIG. 5 presents NGI deposition data for the composition of Example 5;

[0055] FIG. 6 presents NGI deposition data for the composition of Example 6;

[0056] FIG. 7 shows esketamine plasma concentration vs time after administration of various single doses of dry powder composition of Example 2;

[0057] FIG. 8 shows esketamine plasma concentration vs time after administration of a sequence of single doses of dry powder composition of Example 2; and

[0058] FIG. 9 presents adverse effect distribution after administration of dry powder composition of Example 2 (PART A).

[0059] FIG. 10 presents adverse effect distribution after administration of dry powder composition of Example 2. (PART B).

[0060] FIG. 11 is a schematic diagram of the first embodiment of the system for electronically supervised parenteral administration of a pharmaceutical composition with an inhaler according to the invention;

[0061] FIG. 12 is a schematic diagram of the control signal generated by the control station to control an inhaler according to the invention;

[0062] FIG. 13 is a schematic diagram of the inhaler according to the invention;

[0063] FIG. 14 is a schematic diagram of the inhaler with a measurement unit according to the invention;

[0064] FIG. 15 is a schematic diagram of the ranking matrix for use in the system for electronically supervised parenteral administration of a pharmaceutical composition with an inhaler according to the invention;

[0065] FIG. 16 is a schematic diagram of the process of assigning a value of quality measure to a measured physical property using a ranking matrix in the system for electronically supervised parenteral administration of a pharmaceutical composition with an inhaler according to the invention;

[0066] FIG. 17. is a schematic diagram of the second embodiment of the system for electronically supervised parenteral administration of a pharmaceutical composition with an inhaler according to the invention;

[0067] FIG. 18 is a schematic diagram of the another embodiment of the inhaler according to the invention;

[0068] In an embodiment of the invention is an inhaler with a dry powder pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt as a medicine for use in a method of treatment of depression by pulmonary administration, i.e. administration via pulmonary route.

[0069] The inhaler may have ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by pulmonary route as a dry powder pharmaceutical formulation.

[0070] Preferably, in the use according to the invention, esketamine, especially esketamine hydrochloride, is self- administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence of administrations consisting of multiple single doses (inhalation events), such as at least 3 single doses, each inhalation event consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably in 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation (rest period). Preferably, such as sequence lasts at least 30 minutes, for example lasts 30 minutes, and includes 3 sequences of administration and break periods between are preferably equal, i.e. are 15 minutes break (rest) period.

[0071] Preferably, in the use according to the invention, esketamine, especially esketamine hydrochloride, is self- administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation. Such a composition or formulation is described in Example 2 below. Between such each inhalation event (single dose) there is provided a break period without any inhalation, preferably there are two equal breaks lasting about 15 minutes, i.e. first single dose is administered at time 0, second single dose is administered after about 15 minutes and the third single dose is administered at 30 minute. Such a sequence allows to obtain plasma concentration profile that provides plasma concentration infusion at the level having antidepressant effect, as known from prior art tests of intravenous infusions.

[0072] According to the invention, the term “ketamine” encompasses racemic ketamine and its enantiomers esketamine and arketamine, both as a free base and pharmaceutically acceptable salts thereof.

[0073] In a preferred embodiment ketamine is esketamine.

[0074] In another embodiment, ketamine is racemic ketamine.

[0075] Preferred pharmaceutically acceptable ketamine salt is hydrochloride.

[0076] In a most preferred embodiment, the composition of the invention comprises esketamine hydrochloride.

[0077] In another embodiment, the composition of the invention comprises racemic ketamine hydrochloride.

[0078] Preferably, in the use according to the invention, ketamine, especially esketamine such as esketamine hydrochloride, is self-administered pulmonary by a patient by inhalation of a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses (inhalation events), such as at least 3 single doses, each single dose or inhalation event consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably in 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation (rest period). Preferably, such as sequence lasts at least 30 minutes, for example lasts 30 minutes, and includes 3 sequences of administration and break periods between are preferably equal, i.e. are 15 minutes break (rest) period.

[0079] Preferably, in the use according to the invention, esketamine such as esketamine hydrochloride, is self- administered pulmonary by a patient by inhalation of a dry powder esketamine composition or formulation in a sequence lasting 30 minutes consisting of 3 single doses (inhalation events), each inhalation event consisting of 3 or 4 puffs, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation. Such a composition or formulation is described in Example 2 below. Between such each inhalation event (single dose) there is provided a break period without any inhalation, preferably there are two equal breaks lasting about 15 minutes, i.e. first single dose is administered at time 0, second single dose is administered after about 15 minutes and the third single dose is administered at 30 minute. Such a sequence allows to obtain plasma concentration profile that provides plasma concentration infusion at the level having antidepressant effect, as known from prior art tests of intravenous infusions.

[0080] The term “medicine” as used herein can be used interchangeably with the term “medicinal product”. It should be understood that “medicine” and “medicinal product” have essentially the same meaning in terms of the invention.

[0081] The term “treatment-resistant or treatment refractory depression” (TRD) is well known in the art and means depression in patients not responding to at least two prior attempts of adequate antidepressive treatment using commonly known antidepressant therapies. The term is generally described for example in U.S. Pat. No. 8,785,500 and US2015/0056308.

[0082] The term “bipolar disorder” is well known in the art and means a disorder that causes periods of depression and periods of abnormally elevated mood.

[0083] The term “major depression” is well known in the art and means a disorder characterized by at least two weeks of low mood that is present across most situations.

[0084] In one aspect the composition of the invention comprises from 2 mg to 100 mg of ketamine calculated as a free base per nominal unit dose.

[0085] In a particular embodiment, the composition of the invention comprises from 2 mg to 60 mg of ketamine, especially 2 mg to 40 mg of ketamine, such as from 3 mg to 15 mg of ketamine, calculated as a free base, per nominal unit dose.

[0086] In another embodiment, the composition of the invention comprises further one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 3% by weight, with respect to the total weight of the composition.

[0087] The composition comprises ketamine, especially esketamine hydrochloride, having median particle diameter d50 of 1 10 pm, such as 1 8 pm, especially 3 pm, d10 of 0.2 5 pm and d90 of 3 35 pm.

[0088] Median particle size d50 is a parameter obtained by laser diffraction technique with dry dispersion using Sympatec HELOS laser diffractometer attached with ASPIROS feeder. For measurement, raw ketamine, especially esketamine hydrochloride, is dispersed with pressure 3.0 bar in total amount of 30 mg per sample.

[0089] The composition is a dry powder formulation for administration using dry powder inhalers. Conventional and typical dry powder inhalers can be used for this purpose.

[0090] The term “dry powder” is known for a skilled person and should be understood in a manner conventional in the art as a solid mix of particles that is fluidized when the patient inhales after actuation of the inhaler device.

[0091] The term “nominal unit dose” in accordance with the invention relates to the ketamine dose as present (loaded) in the composition that is destined for a single administration. The nominal unit dose can be a measured dose of the dry powder to be ready for the patient to take, contained in a single unit, such as a capsule or single compartment in a blister, or a dose to be taken from for delivery from the multi-dose dry powder reservoir.

[0092] The term “emitted dose” relates to the proportion of the nominal unit dose that exits/leaves the device after inhalation by a patient.

[0093] The dry powder pharmaceutical composition or formulation for use according to the invention may comprise further pharmaceutical excipients., i.e. one or more additives selected from the group consisting of a carbohydrate bulking agent (a carrier) in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 3% by weight, with respect to the total weight of the composition.

[0094] Suitable carbohydrate bulking agent (a carrier) can be lactose, D-mannitol, glucose monohydrate, trehalose, especially trehalose dihydrate, erythritol, dextrose, maltose, sorbitol or xylitol. Especially convenient bulking agent is milled lactose, such as lactose monohydrate or anhydrous lactose, especially lactose monohydrate, having suitable granulometry. Suitable granulometry is defined as having d50 30 200 pm (Sympatec HELOS) as the main coarse fraction (especially 80 pm). Examples of suitable lactose monohydrate commercial grades are Lactohale 200 (LH200), Lactohale 100 (LH100) and Lactohale 200LP. Various types of inhalers may require appropriate selection of lactose grade most suitable for performance thereof. Such a selection is within common skills of a skilled person.

[0095] Typical amount of the bulking agent in the composition of the invention is 30 95% by weight, especially 30 to 80% by weight, with respect to the total weight of the composition.

[0096] Pharmaceutical excipients/additives include also a stabilizer (also called force control agent FCA), i.e. a substance that reduces adhesion and cohesion. Suitable stabilizers are for example magnesium stearate, lecithin, and aminoacids, such as leucine. Especially preferred stabilizer is magnesium stearate.

[0097] Stabilizer “disturbs” the weak binding forces between the small particles and thus helps to keep the particles separated, reduces self-adhesion of small particles and also adherence to other particles in the formulation if such other particles are present, reduces the adhesion to the inner surfaces of the inhaler, as well as improves rheological properties of powder - powder flowability.

[0098] The amount of the stabilizer in the composition of the invention is 0.2 3% by weight, especially 0.8% by weight, with respect to the total weight of the composition.

[0099] Composition or formulation for use according to the invention is prepared by blending in a high-shear mixer a bulking agent/carrier of suitable granulometry with a stabilizer, and then adding ketamine, especially esketamine hydrochloride, of suitable granulometry and again blending in a high-shear mixer.

[0100] Alternatively, ketamine, especially esketamine hydrochloride, of suitable granulometry is co-processed (blended) with a stabilizer in a high-shear mixer, and then the bulking agent/carrier is added and again mixed in a high-shear mixer.

[0101] The composition is a dry powder formulation for administration using dry powder inhalers. Conventional and typical dry powder inhalers can be used for this purpose.

[0102] The formulation may be administered by three device categories: single-unit dose inhaler in which each dose, such as in a capsule, is loaded into the device before use; a multi-dose reservoir inhaler in which a bulk supply of dry powder with plurality of doses is preloaded into the device; and a multi-unit dose inhaler in which a plurality of single doses are individually sealed in separate compartments such as in a blister cavity, and discharged each time the device is actuated. Preferred is the multi-unit dose inhaler in which a plurality of single doses are individually sealed, such as in the blister, and discharged each time the device is actuated.

[0103] In one embodiment of the use according to the invention as defined above, the medicine for administration via pulmonary route is a blister with plurality of individual nominal unit doses premetered and individually sealed. One preferred example of such an inhaler is Diskus type inhaler.

[0104] In another embodiment of the use according to the invention as defined above, the medicine for administration via pulmonary route is a capsule with a single nominal unit dose.

[0105] In another embodiment of the use according to the invention as defined above, the medicine for administration of a single dose via pulmonary route is a multi-dose powder reservoir.

[0106] The composition for use according to the invention provides emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride.

[0107] The composition for use according to the invention provides the fraction of the dose delivered locally directly to the lungs that is at least 40%, such as from 40 to 50%, especially 40% to 60%, especially up to 85%, of the emitted unit dose.

[0108] Emitted dose is the portion of nominal unit dose that is emitted from the inhaler device and leaves the inhaler device as an aerosol and hence is available to the patient.

[0109] Only part of emitted dose reaches the lungs and thus circulating blood of a patient as the dose delivered to the lungs (also called Fine Particle Dose - FPD) or fraction delivered to the lungs (also called Fine Particle Fraction FPF). Some part reaches gastrointestinal tract via oropharyngeal and oral routes, i.e. is swallowed, and is accessible for undesired first-part metabolism.

[0110] It has been surprisingly found that in spite of well-known problems with inhalation dry powder formulation of high doses of an active substance for pulmonary administration, the uniform and stable high-dose ketamine, especially esketamine hydrochloride dry powder composition can be obtained that when administered by pulmonary route provides therapeutic ketamine level in the circulating blood of a patient, i.e. at least 50 to 100 ng/ml, such as 70 to 100 ng/ml, such as 70-80 ng/ml, such as about 100 ng/ml. Therapeutic ketamine level relates to the level in the blood that is effective in the treatment of depression, especially major depressive disorder, such as treatment resistant or treatment-refractory depression, and may be dependent on the subject, gender, age, severity of the disease, the type of the inhaler, and may vary depending on whether ketamine is racemic ketamine or enantiomeric ketamine.

[0111] The fraction of the emitted dose delivered to the lungs is surprisingly high, in contrast with typical inhalation compositions wherein the standard is that only 15 to 20% of the emitted dose is delivered to the lungs.

[0112] The fraction of the emitted dose delivered locally directly to the lungs (also called Fine Particle Fraction FPF) can be determined using well-known and conventional methods and assays. Such methods and assays include any of those described in European Pharmacopeia 9.0, Chapter 2.9.18, Preparations for inhalation; Aerodynamic assessment of fine particles for determination of Fine Particle Dose. In particular, the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) can be used to assess and control the aerodynamic particle size distribution (APSD). The NGI apparatus is as presented in FIGS. 2.9.18.- 12 and 2.9.18.-13 on page 333 of European Pharmacopeia 9.0.

[0113] Emitted dose and fine particle dose and fraction (FPF and FPD) are strongly dependent on two factors i.e. on the formulation and on the device. For the device the most discriminatory factor for emitted dose is resistance. The resistance of a dry powder inhaler (DPI) is an intrinsic value which depends on the design of the inhalation channel, the metering cup and the air inlets. DPIs can be classified into four resistance groups (low, medium, medium-high, high) with respect to the inhalation flow required to produce a pressure drop of 4 kPa. This value was chosen because it is the one recommended by pharmacopoeia for the in vitro characterization of the dose emitted from a DPI. Additionally for capsule-based DPIs can be limited by the powder retention in the capsule and device, which lead to reduction in the emitted dose.

[0114] Emitted dose testing is relatively straightforward. The device is ‘fired’ into a sampling apparatus that enables the capture of the measured dose on a filter. The aerodynamic particle size distribution of inhaled products is measured using the technique of multistage cascade impaction, here Next Generation Impactor (NGI). The collected quantity of active ingredient is determined further by HPLC analysis. The inhalers are tested at a predetermined flow rate, and the pressure drop across the inhaler is 4.0 kPa in line with the Ph Eur.

[0115] Efficient particle capture is ensured by coating the particle collection surface of each of stages 1-7, as well as the MOC and the pre-separator base, with a coating substance. The central cup of the pre-separator is filled with adequate diluent.

[0116] After discharging the powder to the NGI (Number of actuations per impactor n=1 for one analysis) by opening the two-way solenoid valve for the required time at flow control which generate pressure drop across the inhaler 4 kPa the following operations are performed:

[0117] I. Stages 1 to 7 and MOC. Each stage is washed with appropriate diluent (extraction of drug substance). NGI tray loaded with the cups on a Copley Gentle Rocker is gently shaken for 10 minutes.

[0118] II. Mouthpiece adapter. Deposited inhalation powder on adapter is rinsed with appropriate diluent a volumetric flask and sonicated for 10 minutes.

[0119] III. Induction port. Deposited inhalation powder from induction port is rinsed with appropriate diluent into a volumetric flask and sonicated for 10 minutes.

[0120] IV. Preseparator. Deposited inhalation powder from these component is rinsed with appropriate diluent into a volumetric flask and sonicated for 10 minutes.

[0121] Finally collected samples from each stage of impactor are filtered analyzed by high-performance liquid chromatography

[0122] Composition of for use according to the invention has an appropriate ketamine, in particular esketamine hydrochloride pharmacokinetics profile that enables achievement of approximately 50 to 100 ng/ml of the ketamine plasma concentration over 40 minutes after pulmonary administration directly to the lungs by inhalation. Said plasma concentration corresponds to antidepressive effect. Maintaining this concentration over time mimics 40-minute intravenous infusion known to be effective in depression and well-tolerated.

[0123] The present invention will now be with reference to the accompanying examples, which are not intended to be limiting.

EXAMPLES

[0124] General manufacturing procedure:

[0125] A sum of lactose monohydrate and magnesium stearate are sieved through 0.25 mm mesh and mixed in high-shear mixer for 3 minutes. Obtained mixture is sieved with active substance through 0.5 mm mesh and mixed in high-shear mixer for 5 minutes.

[0126] To eliminate electrostatic charges, antistatic PE bags are used during the process.

[0127] Vacuum filling process (blisters):

[0128] Vacuum-drum technology dose forming process is used for blister filling. The blister cavity is in volume range of 15 to 45 mm3 (especially ca. 30 mm3). Powder which is filled into cavity is in amount of 10 30 mg (especially 23 mg).

[0129] During process parameters of vacuum-drum device are:

[0130] Vacuum pressure: -0 500 mBar, especially 50 400 mBar

[0131] Fluidization pressure: - 0.1 - -0.4 Bar

[0132] Fluidization time: 50 2000 ms, especially 50 -300 ms

[0133] Filling time: 50 700 ms, especially 50 400 ms

[0134] Sealing time: 100 600ms

[0135] Sealing tests of filled blisters are performed under vacuum.

[0136] Finally, the blister strips are coiled into the inhaler.

[0137] Filling process (capsules):

[0138] Capsules to be filled are placed in the sockets closed ends down. Powder is discharged from the dosator and comes directly to the capsules. The powder with which the capsules are to be filled is placed in the dosator, may be tamped and discharged into the capsules.

[0139] During the process parameters of capsule filling device are:

[0140] Rotation: 1- 70 rpm

[0141] Tamping high: 1 10mm

[0142] Dosator high: 1 250mm

[0143] Finally, the filled capsules are mounted into the inhaler.

[0144] Ketamine dry inhalation powder for blisters and capsules

[0145] The following compositions has been prepared in accordance with the above general procedure in the scale of 0.9 kg.

TABLE-US-00001 Component Amount (mg/unit) Example 1 Esketamine hydrochloride 3.45 (corresponds to 2.99 mg esketamine) Lactose monohydrate LH200 LP 19.16 Magnesium stearate  0.39 Example 2 Esketamine hydrochloride 4.61 (corresponds to 4 mg esketamine) Lactose monohydrate LH200 LP 18.20 Magnesium stearate  0.18 Example 3 Esketamine hydrochloride 5.06 (corresponds to 4.39 mg esketamine) Lactose monohydrate LH200 LP  17.581 Magnesium stearate  0.359

[0146] The compositions have been found uniform in accordance with requirements of Ph.Eur.2.9.40. Average esketamine hydrochloride content (n=10) was in the range 92.5% - 107.5% of nominal dose.

[0147] The process has been found scalable to the scale of 1.8 kg.

[0148] Aerodynamic Particle Size Distribution (APSD) test of the compositions of the Examples 1, 2 and 3 of the composition according to the invention.

[0149] The compositions of Examples 1, 2 and 3 of the invention have been tested using the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) in accordance with the procedure for powder inhalers.

[0150] The results of the tests are presented in Table 1 below and in FIG. 1 (Example 1), FIG. 2 (Example 2) and FIG. 3 (Example 3) of the drawing, wherein upper diagrams present APSD data for the whole NGI and bottom diagrams present APSD data for stages 1-7 and MOC. The following abbreviations are used for the results of the tests:

[0151] MA-mouth adapter

[0152] T-induction port

[0153] PS-Pre-separator

[0154] S1-S7 -stages of NGI

[0155] MOC-micro-orifice collector

[0156] ISM-Impactor sized mass; mass entering the impactor excluding non-sizing portions

[0157] MMAD (μm)-mass median aerodynamic diameter. Defined as the diameter at which 50% of the particles by mass are larger and 50% are smaller.

[0158] GSD-geometric standard deviation. Measure of the spread of an aerodynamic particle size distribution

[0159] FPF-fine particle fraction (%)

[0160] FPD-fine particle dose

TABLE-US-00002 TABLE 1 NGI deposition data Example No 1 2 3 MA [mg] 0.043 0.194 0.074 T 0.166 0.713 0.740 PS 0.598 0.262 0.825 S1 0.063 0.157 0.179 S2 0.193 0.599 0.541 S3 0.308 0.538 0.588 S4 0.243 0.392 0.345 S5 0.112 0.201 0.179 S6 0.061 0.121 0.105 S7 0.048 0.087 0.070 MOC 0.037 0.054 0.054 ISM (mg) 1.00 1.99 1.88 Total Mass on Impactor (mg) 1.07 2.15 2.06 Total Mass on System (mg) 1.87 3.32 3.70 Mass on Impactor/Actuation (mg) 1.07 2.15 2.06 Mass on System/Actuation (mg) 1.87 3.32 3.70 FPD ≤ 5.0 mcm (mg) esketamine 1.0 1.7 1.6 FPF ≤ 5.0 mcm (%) 49.0 51.0 44.0 MMAD (mcm) 2.6 2.9 3.0 GSD 1.8 1.8 1.8

[0161] The obtained results showed a product with expected quality attributes.

[0162] The composition of the invention demonstrated appropriate homogeneity and a very high level of fine particle fractions, with:

[0163] FPF >49%, FPD 1.0 mg; and emitted dose: 2.3 mg, for Example 1

[0164] FPF >47%, FPD: 1.7 mg; and emitted dose: 3.6 mg, for Example 2, and

[0165] FPF >44%, FPD: 1.6 mg; and emitted dose: 3.9 mg, for Example 3.

[0166] Esketamine dry inhalation powder for capsules The following compositions has been prepared in accordance with the above general procedure in the scale of 0.9 kg.

TABLE-US-00003 Component Amount (mg/unit) Example 4 Esketamine hydrochloride 5.00 (corresponds to 4.34 mg esketamine) Lactose monohydrate LH200 LP 19.8 Magnesium stearate  0.2 Example 5 Esketamine hydrochloride 10.00 (corresponds to 8.67 mg esketamine) Lactose monohydrate LH200 LP 39.6 Magnesium stearate  0.4 Example 6 Esketamine hydrochloride 20.00 (corresponds to 17.34 mg esketamine) Lactose monohydrate LH200 LP 79.2 Magnesium stearate  0.8

[0167] Aerodynamic Particle Size Distribution (APSD) test of the compositions of Examples 4, 5 and 6 of the invention.

[0168] The compositions of Examples 4, 5 and 6 of the invention have been tested using the Next Generation Pharmaceutical Impactor (NGI) (Ph. Eur. Apparatus E) in accordance with the procedure for powder inhalers.

[0169] The results of the tests are presented in Table 2 below and in FIG. 4 (Example 4), FIG. 5 (Example 5) and FIG. 6 (Example 6) of the drawing, wherein higher diagrams present APSD data for the whole NGI and lower diagrams present APSD data stages 1-7 and MOC.

TABLE-US-00004 TABLE 2 NGI deposition data Example No 4 5 6 MA [mg] 0.090 0.174 0.329 T 0.655 1.328 2.877 PS 0.262 0.774 1.838 S1 0.368 0.669 1.621 S2 0.915 1.505 3.293 S3 0.631 1.057 2.270 S4 0.449 0.705 1.386 S5 0.273 0.414 0.719 S6 0.167 0.300 0.505 S7 0.108 0.214 0.374 MOC 0.061 0.166 0.283 ISM (mg) 2.61 4.36 8.83 Total Mass on Impactor (mg) 2.97 5.03 10.45 Total Mass on System (mg) 3.98 7.30 15.49 Mass on Impactor/Actuation (mg) 2.97 5.03 10.45 Mass on System/Actuation (mg) 3.98 7.30 15.49 FPD ≤ 5.0 mcm (mg) esketamine 2.4 3.9 7.9 FPF ≤ 5.0 mcm (%) 59 54 51 MMAD (mcm) 3.0 3.0 3.2 GSD 1.9 1.9 2.6

[0170] The obtained results showed a product with expected quality attributes.

[0171] The invented formulation demonstrated appropriate homogeneity and a very high level of fine particle fractions, with:

[0172] FPF >59%, FPD 2.4 mg; emitted dose: 4.2 mg, for Example 4

[0173] FPF >54%, FPD: 3.9 mg; emitted dose: 7.1 mg, for Example 5, and

[0174] FPF >51%, FPD: 7.9 mg; emitted dose: 16.5 mg, for Example 6.

[0175] The dry powder pharmaceutical composition of the invention provided emitted esketamine hydrochloride dose at the level up to 97%, such as up to 85% of the nominal dose and at least 40% of fine particle fraction (fraction delivered to the lungs) for emitted esketamine dose.

[0176] Example 7

[0177] Pharmacokinetics of inhaled esketamine dry powder in healthy volunteers

[0178] Esketamine hydrochloride dry powder formulation of Example 2 was administered to healthy volunteers pulmonary, i.e. directly to the lungs using dry powder inhaler (DPI) (by self-administration).

[0179] One puff of dry powder formulation contained 4.6 mg of esketamine hydrochloride, corresponding to 4 mg of esketamine free base and excipients 18.22 mg of lactose monohydrate and 0.18 mg of magnesium stearate.

[0180] A single dose was an inhalation events consisting of 1 to 6 puffs, i.e. 4 to 24 mg of esketamine free base nominal dose.

[0181] In part A of the study, designed as a one-centre single ascending dose, the medicine was delivered in a single dose once daily (up to 6 consecutive puffs) to 18 healthy volunteer subjects. Subjects were divided into 6 cohorts, cohorts receiving 1, 2, 3, 4, 5 or 6 puffs in a single doses (inhalation events), respectively.

[0182] Collection of blood samples for determination of esketamine and esnorketamine concentration and calculation of pharmacokinetic parameters was performed for up 24 hours following the start of the test.

[0183] The aim of the study was to determine the amount of puffs needed to obtain plasma concentration similar to that sufficient to achieve antidepressant effect as for 0.20 mg/kg 40 minutes intravenous infusion. It can be predicted on the basis of literature data that this corresponds to concentration at 40 min of infusion between about 60 to 100 ng/ml. It was also the aim to determine the number of puffs that allow to avoid a sharp peak of plasma concentration that is considered an important factor inducing adverse psychomimetic and dissociative effects.

[0184] The results of the part A of the test are presented on FIG. 7 that shows esketamine plasma concentration over time after administration of various single doses of dry powder composition of Example 2. As it can be seen, the number of puffs that allows to obtain plasma esketamine concentration sufficient for antidepressant effect and without sharp peak of said concentration was determined to be 1 to 4 puffs, corresponding to 4 to 16 mg of esketamine free base nominal dose.

[0185] Therefore, a single dose (inhalation event) consisting of 1 to 4 puffs was selected for the next Part B of the test.

[0186] In part B of the study the composition of Example 2 was administered to 12 healthy volunteer subjects divided into 4 cohorts in four different single doses each cohort (i.e. each single dose consisting of 1, 2, 3 or 4 puffs, respectively) in one day in the administration sequence consisting of three administrations of single dose (inhalation event) in the period of 30 minutes, Between inhalation events there were 15 minutes break periods, i.e. first single dose was administered at 0 min., second single dose was administered at 15 min, and third single dose was administered at 30 min.

[0187] The aim of Part B was to investigate pharmacokinetic properties of esketamine following different dosing schemes in healthy subjects and determine the scheme that enables achievement of the appropriate plasma concentration over time to mimic the 40-minute intravenous infusion (part B),

[0188] The results of the of the part B of the test are presented on FIG. 8 that shows esketamine plasma concentration over time after administration of various single doses of dry powder composition of Example 2 in a sequence of 3 administrations of single doses during 30 minutes. FIG. 8 shows also (the area between two bold black lines) a simulation of esketamine plasma concentration after 0.2 mg/kg 40 minutes i.v. infusion.

[0189] As it can be seen form FIG. 8, sequence of administration of 3 single doses consisting of 3 or 4 puffs allowed to obtain plasma concentration profile mimicking quite well esketamine intravenous infusion at the level corresponding to antidepressant effect.

[0190] Both in Part A and Part B of the study the adverse effects were monitored and assessed by a psychiatrist. The summary of the adverse effects is presented in FIG. 9. As can be seen, no serious effects were observed, all adverse effects being assessed as mild, occasionally moderate. Psychomimetic effects were transient, lasting up to 30 minutes following administration. There were no discontinuations due to adverse effects or toxicity.

[0191] The above shows that pulmonary administration of esketamine, i.e. directly to the lungs is a promising way of treating depression, in particular TRD, by convenient self-administration by a patient. Plasma concentration profile is quite smooth, consistent with a target profile and safe for chronic administration.

[0192] The system for electronically supervised administration of a pharmaceutical composition according to the present invention is disclosed in a non-limiting embodiment relating to a dry powder inhaler used in therapy of a drug resistant depression.

[0193] The system for electronically supervised parenteral administration of a pharmaceutical composition with an inhaler according to the present invention comprises a digital communications means, a control terminal for an authorised entity, and an inhaler for administration of a pharmaceutical composition. Preferably, an inhaler may be provided with sensors for measuring at least one physical property characterizing administration process from a perspective of an inside of the inhaler, and further a system may comprise a processing station that is adapted to convert the measured physical value and convert it into a quality measure of the administration process.

[0194] In the embodiment of the system presented on FIG. 11 a system 1 comprises several nodes: a control terminal 100 for an authorised entity, a processing station 200 and an inhaler 400 for administration of a pharmaceutical composition, along with a patient's mobile device 300. Communications means are depicted symbolically by arrows which are elements of the communication system capable of establishing a communication link between the system nodes, preferably a secure encrypted communication link with a use of TLS/SSL encryption protocols.

[0195] A communications means might be any standard communications means of digital communication known in the art capable of transmitting a message frames between nodes of the system, this includes cable, wireless, ground or satellite communications systems supporting Internet communications protocols TCP/IP. The communication means covers also near field communications systems, like NFC, Bluetooth, etc. These are particularly suitable for establishing a communication link between a patient's mobile device 300 and the inhaler 400.

[0196] The mobile device 300 is a mobile phone, tablet, electronic watch, band or any other handheld or wearable device with a user interface, memory, processing means and communications means. The mobile device needs to be provided with an unique identification data allowing to distinguish this device from other devices.

[0197] In the first embodiment of the invention a control terminal 100 is a computer terminal provided with a user interface allowing interaction of the authorised entity with the control terminal 100. The authorised entity might be a physician that has selected particular treatment to the patient that needs to be implemented with a use of the inhaler 400 being part of the system 1 according to the invention. However, the authorised entity might also be an institution or a number of institutions within the local health care system. For example the authorised entity may comprise of a physician selecting the treatment for a patient by issuing a regular prescription, a pharmacist working in a drug store who is going to issue the inhaler to the patient or a pharmaceutical company manufacturing inhalers loaded with the pharmaceutical composition. The common feature of the authorised entity is that at least one person within the entity has an authorisation to qualify the particular identified patient for therapy with a use of the pharmaceutical composition distributed within the inhaler 400, and there is at least one terminal that is generating a control signal 5 with an administration scheme 11 and an authorisation token 12 for assigning to a patient's mobile device 300. Preferably the authorisation entity may be one person, e.g. a physician issuing a prescription, however a distributed authorisation entity of the functionality described above is equally feasible.

[0198] FIG. 12 shows the control signal 5, the control signal 5 is generated when the administration scheme 11 is selected for the patient. The control signal 5 comprises a unique identification data 10 of the control signal, with an administration scheme 11 and an authorisation token 12 for assigning to a patient's mobile device, and a security block 13. By generating both the data corresponding to an administration scheme 11 and the authorisation token 12 for the mobile device 300, the system 1 is simplified because the authorised entity is required to communicate only with the mobile device 300. It is not necessary for the authorised entity to communicate additionally with the medical device 400 directly. By providing the data corresponding to an administration scheme 11 and the authorisation token 12 in the same signal, the system 1 is simplified because only one signal 5 is required.

[0199] The identification data 10 may be an ID code of the control signal 5 or a signal ID header comprising a time stamp, a serial number of the control signal, a prescription number etc. The primary function of the identification block 10 is to uniquely identify an event of generation of a control signal 5.

[0200] The administration scheme 11 is part of the control signal 5, that identifies the pharmaceutical composition and administration parameters prescribed for the patient. The administration scheme 11 might be simply an identifier of the approved standard therapy, or set of data indicating the pharmaceutical composition, administration regime, dose etc, or it may be a set of data that identifies the pharmaceutical composition while the administration scheme is personalized according to the therapeutic needs of the patient. Preferably the control terminal 100 is provided with a cross checking function that is cross checking the personalized parameters of the administration scheme with approved ranges.

[0201] The authorisation token 12 is part of the control signal that is unique to the control signal and represents the approval to use the prescribed pharmaceutical composition by the patient. This might be a serial number or hash unique for the approval granted. The authorisation token might be a pure electronic code, or might have a physical form of a sticker or tag provided with an insignia readable by the mobile devices, e.g. 3D code, 2D code, OR code, NFC tag. Hence, the authorisation token 12 may be provided separately from the control signal 5.

[0202] The security block 13 comprises data allowing verification of the integrity of the control signal 5, and allowing to identify the authorised entity that issued the control signal 5. This can be a block comprising digital certificate of the authorised authority that generated the control signal 5, and a hash block generated for the control signal 5 with a use of the digital certificate. The security block may implement any feasible integrity control system.

[0203] Preferably the control signal 5 is encrypted, and the communication means implements secure communication channels as, for example, with the use of the known protocols and encryption schemes.

[0204] The control signal 5 might be a single data packet/message or a collection of independent packets or messages linked in a way providing its integrity and functionality as described above. For example the administration scheme 11 might be one of a number of different standard administration schemes stored in the memory of the inhaler 400 with their identifiers, while the control signal 5 generated by the physician comprises only an identifier pointing to the administration schemes to be applied. Alternatively, a control signal 5 is generated by a pharmacist based on a prescription issued by a physician, and includes an identifier of the administration scheme and an authorisation token issued by the pharmaceuticals company being responsible for manufacturing the pharmaceutical composition within the inhaler.

[0205] When a physician qualifies a patient for the treatment with a pharmaceutical composition via an inhaler according to the invention the administration scheme is selected. Thus, the first element of the control signal 5 is being created. At this time the physician can issue a prescription for the inhaler 400 to be collected at the pharmacy, or alternatively, it can provide the patient with the inhaler 400. The moment the inhaler 400 is provided to the patient, the authorisation token 12 is assigned to the patient's mobile device 300. Alternatively, the authorisation token 12 is assigned to the mobile device 300 of a patient when the prescription for an inhaler 400 is issued by the physician.

[0206] Assignment of the authorisation token 12 to the mobile device 300 comprises a step of transferring the authorisation token 12 to the memory of the mobile device 300. This transfer may take several forms, e.g. by scanning a QR code with an authorisation token generated by the pharmaceutical company by the camera of the mobile device that is further decoded by the software of the mobile device 300 and stored in the memory of the mobile device 300. Further, assignment of the authorisation token 12 to the mobile device 300 comprises a step of transferring the authorisation token 12 along with an identification data of the mobile device 300 to the authorised entity that issued a control signal 5.

[0207] In order to perform the assignment steps the patient's mobile device 300 needs to be provided with a software application allowing transferring the authorisation token 12 to the memory of the mobile device and further communicating the authorisation token 12 with the mobile device 300 identification data to the processing station 200 of the authorised entity responsible for generating a control signal 5. The processing station 200 assigns the authorisation token 12 to the mobile device 300 using a mobile device's identification data, linking the mobile device 300 with the authorisation token 12. The processing station 200 generates a confirmation of assigning a mobile device 300 with the authorisation token 12 and sends back this confirmation to the mobile device 300. The mobile device 300 is also adapted to receive from a processing station 200 a confirmation of assigning the authorisation token 12 to the mobile device 300.

[0208] The inhaler 400 according to the present invention as presented on FIG. 13 comprises a communications unit 401, a processing unit 402 comprising a clock, a controlled blocking unit 403, a memory unit 404, a pharmaceutical composition storage 410 and a pharmaceutical composition administration unit 411. As shown on FIG. 14 the inhaler 400 preferably is provided with a measurement unit 405 that is provided with a sensor adapted to measure a physical property of the administration process of the pharmaceutical composition. The sensor unit 405 may comprise a microphone, and the measured physical property may be an amplitude of a sound wave. The microphone may be placed inside the mixing chamber where a dry powder pharmaceutical composition is mixed with air during the inhalation.

[0209] The inhaler 400 is a device preloaded with a pharmaceutical composition and adapted to administer the pharmaceutical composition in a predetermined doses. Preferably the inhaler 400 is a sealed inhaler. It means it does not allow to refill or open or modify the content of the storage unit 410 for a pharmaceutical composition. Alternatively, the inhaler 400 is adapted to allow replacing the content of the storage unit 410 in a controlled manner.

[0210] A patient who received the inhaler 400 and was assigned the authorisation token 12 to the patient's mobile device 300, registers in the inhaler 400 the authorisation token 12 assigned to the mobile device 300.

[0211] Registration of the authorisation token 12 assigned to the mobile device 300 means transferring the authorisation token 12 assigned to the patient's mobile device 300 into the memory of the inhaler 400. Alternatively, the inhaler 400 registers a confirmation that the authorisation token 12 has been assigned to the patient's mobile device 300. This can be done via the communications means establishing a communication channel between the inhaler 400 and the mobile device 300. Preferably the communication channel is a near field or close range communication channel or the communication channel enables the distance measurement between the mobile device 300 and the inhaler 400.

[0212] In response to registration of the authorisation token 12 assigned to the mobile device 300 with the inhaler 400, the inhaler 400 processes the administration scheme 11. Processing the administration scheme means the inhaler 400 makes the administration scheme 11 an active administration scheme and allows administration of the doses of a pharmaceutical composition in a time windows indicated by the administration scheme 11. In order to follow the administration schemes the inhaler 400 is provided with a controlled blocking means 403 that effectively blocks the transfer of a dose of the pharmaceutical composition from the storage 410 to the administration unit 411, and upon receiving a control signal from the processing unit 402 allows the transfer of a dose of the pharmaceutical composition from the storage 410 to the administration unit 411.

[0213] The blocking means 403 comprises for an example a valve, pin, bolt, relay, key, normally closed switch or any form of actuator that is in a blocking position that blocks the transfer of a dose of the pharmaceutical composition from the storage 410 to the administration unit 411, and may be positioned in an open position allowing administration of the pharmaceutical composition in response to a control signal from the control unit 402. The blocking means 403 is normally closed (normally closed type) and opens only according to the active administration scheme 12. The controlled blocking means 403 may comprise a drive unit and active actuating element that blocks the transfer of a dose of the dry powder pharmaceutical composition from the storage 410 to the administration unit 411. The actuating element in a blocking state may block the transfer of a dose of the pharmaceutical composition from the storage 410 to the administration unit 411, and in an open position allows administration of the pharmaceutical composition in response to a control signal from the control unit 402. Upon receiving a control signal from the processing unit 402 the actuating element may move into an open state and allow administration of the pharmaceutical composition.

[0214] Further, the inhaler 400 is adapted in a such way that a controlled blocking means 403 allows the administration of a pharmaceutical composition stored in the storage 410 only with compliance with the administration scheme 11 and in the presence of the patient's mobile device 300 with the authorisation token 12 assigned thereto. The presence of the patient's mobile device 300 shall be understood as the mobile device 300 being in a proximity of the inhaler 400, i.e. the distance between these two devices being less than 10 meters, preferably less than 5 m, most preferably less than 2 m. By providing the mobile device 300 with the authorisation token 12 and requiring the mobile device 300 to be present, the system 1 is more secure than systems that require the patient to authenticate himself directly on the medical device 400. This is because the pharmaceutical composition can be administered only when the mobile device 300 is present, rather than only requiring the presence of the medical device 400. As a result, the system 1 is secure even if an unauthorised person has the medical device 400 and the patient's passcode, for example.

[0215] Therefore, the inhaler 400 is adapted to cross-check the presence of the mobile device 300 in the proximity of the inhaler 400. This can be achieved by a number of methods, for example using a close range communication means. In such solution a lack of communication connection between the inhaler 400 and the mobile device 300 is understood as being out of range position of the two, hence, the distance between the two devices is larger than expected.

[0216] Alternatively, the inhaler 400 is provided with a range finder that actively or passively determines the distance between the inhaler 400 and the mobile device 300, for example a laser rangefinder, acoustic range finder, time delay measurement system, phase-shift rangefinders, etc.

[0217] If the distance between the mobile device 300 and the inhaler 400 is larger than the prescribed limit, this makes one of the conditions for administration of the pharmaceutical composition missing, therefore, the processing unit 402 is not sending a control signal to the controlled blocking means 403, this does not allow the administration of the pharmaceutical composition. The administration of the pharmaceutical composition is possible only when both conditions are fulfilled, i.e.: [0218] a) the clock of the control unit 402 indicates the time fall within the time window of administration of a dose according to the active administration scheme 11, and [0219] b) the patient's mobile device 300 with the assigned authorisation token 12 is in the proximity of the inhaler 400.

[0220] System 1 according to the invention by combining these two conditions provides an effective way to control abuse and misuse of the pharmaceutical composition. First of all, assigning the authorisation token 12 to the patient's mobile device 300 guaranties the inhaler 400 can be activated only by the authorised person. This is due to the fact of a new phenomenon observed which strongly binds the person with a mobile device on an emotional level.

[0221] As shown on FIG. 14 the inhaler 400 preferably is provided with a measurement unit 405 that is provided with a sensor adapted to measure a physical property of the administration process of the pharmaceutical composition. The physical property of the pharmaceutical composition administration process measured within the inhaler 400 during the administration process is an air pressure, sound intensity, vibration magnitude or any combination of such physical properties. This measurement of the internal physical process that happens inside the inhaler allows to get information confirming the dose has been administered and information about the quality of the administration process i.e. was this process a correct or a failed one. The information on the fact the dose has been administered and on the quality of the administration process is valuable information that can assess the compliance of the patient with the administration scheme and quality of the performance of the patient when the administration process requires active participation of the patient as this is a case in dry powder inhalators when the pharmaceutical composition is excited by air inhaled by the patient. The quality of such process depends on the airflow generated by the patient when taking a dose.

[0222] The data gathered during the administration process are communicated to the processing station 200 of the authorised entity. The processing station 200 is adapted to convert the convert data representing the measured physical property into a quality measure of the administration process. Preferably the quality measure is a value of an abstract index such as 0 or 1, or a grade composed of natural number between 0 and 10, or any other valued measure that is capable of representing the quality of the administration process. This value can be calculated based on a function based on a single variable or multivariable, differential equation or set of equation, fed by measured values of the physical property or properties in time domain, frequency domain or in any suitable transform formed.

[0223] Preferably the value of the quality measure is selected based on a heuristic observations that allow to assign the value of quality measure to the pattern being a representation of the measured physical property in time domain or frequency domain. Preferably within a process of heuristic observations a ranking matrix 500 is produced as shown on FIG. 15. The ranking matrix 500 comprises a set of fields comprising patterns 420 representing measured values of the physical property as explained above. The fields in the ranking matrix are organised into two areas divided by a solid border 501, each pattern received having an assigned quality measure of the administration process. An organisation of fields in the ranking matrix into two separate areas with different quality values is not required, the ranking matrix 500 may be scattered and fields need not to create continued areas with solid boundaries. The ranking matrix 500 works as long as each and every field of the matrix 502 with a specific pattern has an assigned quality value. For example field 503 has an assigned quality value 504 of 0 and the filed 505 has an assigned quality value 506 of 1.

[0224] FIG. 16 shows the process of obtaining a quality measure value from the ranking matrix 500 for a pattern 420 measured within the inhaler 400. The pattern 420 representing measured values of the physical property is compared with patterns in fields of the ranking matrix 500 in order to establish a measure of similarity. The measure of similarity is selected using known methods of establishing a similarity, like mean square error, least squares etc. The pattern in the ranking matrix 500 for which the best similarity measure is identified, for example for which the mean square error is the smallest, is considered the best fit and the quality value 510 assigned to this field is returned in the result of this process. This process can be described as best fit rule for selecting a value of a quality measure.

[0225] The processing station 200 is adapted to communicate the value 510 of the quality measure of the administration process to the control terminal 100 when the control terminal 100 is operated by the physician that qualified the patient for treatment with a pharmaceutical composition. The control terminal is adapted to present the received quality measure of the pharmaceutical composition administration process to the physician or authorised entity using the user interface. This feed-back loop allows to asses a compliance of the patient with an administration scheme. Such information can be used to amend the administration scheme of the present pharmaceutical composition or switch to a different pharmaceutical composition if a current treatment lacks of effect though the administration of the pharmaceutical composition was correct.

[0226] The processing station 200 preferably returns the value 510 of the quality measure of the administration process to the patient's mobile device 300, this improves the self-control of the patient and supports the patient's motivation by confronting the patient with a quality measure. All these factors improve the compliance of the patient with an administration scheme and have a positive therapeutic effect.

[0227] Preferably the processing station 200 is selected from a group of processing devices comprising mobile phone, personal computer, mainframe computer, cloud computing system or any combination of such computing devices with communication, processing and storage capabilities suitable for the processing digital signal and handle database operation, with a controlled access. As described above the processing station 200 performs two functions within the system according to the present invention. The processing station 200 is assigning the patient's mobile devices with an authorisation tokens, and further the processing station 200 is converting the measured physical property into a quality measure of a value representing quality of the pharmaceutical composition's administration process/event.

[0228] Having in place the system for electronically supervised parenteral administration of a pharmaceutical composition a new method for treatment of a disease in a patient in need thereof is obtained. The method comprising parenteral self-administration of pharmaceutical composition by said patient via medical device in a remotely dictated and controlled manner in accordance with a self-administration scheme 11 prescribed by the attending physician, in the presence of a patient's mobile device 300 with an authorisation token 12 assigned thereto, wherein said medical device is operated in compliance with the self-administration scheme 11 via a controlled blocking means 403 adapted to allow administration of a pharmaceutical composition only with compliance with the administration scheme 11 in the presence of a patient's mobile device 300 with the authorisation token 12 assigned thereto.

[0229] Administration process is allowed by the controlled blocking means 403 only with compliance with the administration scheme and in the presence of a patient's mobile device 300 with the authorisation token 12 assigned thereto. This two levels of control delegate the supervision over the administration of the pharmaceutical composition to the electronic system.

[0230] As the administration is protected by the controlled blocking means 403 against misuse or abuse by the patient or a third person it can be safely applied to a rage of substances that in the past required personal supervision of the qualified personnel.

[0231] In the second embodiment of the invention as shown on FIG. 17 the system 1 comprises a processing station 200 adapted to transmit the control signal to the inhaler, and wherein the inhaler receives the control signal with the administration scheme from the processing station in response to registration of the authorisation token with the inhaler. This alternative route might be more convenient in the countries where the physicians do not have a computer or the communication networks do not offer stability required to generate the authorisation token when qualifying the patient for the treatment. This scheme can be also applied when the physicians are needed to be released from administrative tasks.

[0232] The second embodiment of the system provides the same level of security and is equally robust to third party interreference. In the second embodiment the processing station 200 takes over a communication function from the control station 100. A communication channel between the control station 100 and processing station 200 may be of a different character that the communication channel established between the processing station 200 and the mobile device 300.

[0233] FIG. 18 shows a another embodiment of the inhaler 400 according to the invention for use in treatment of depression. This inhaler comprises a storage 410, that holds a blister of a single doses of a dry powder pharmaceutical composition. In this embodiment a pharmaceutical composition is an esketamine in a form of a dry powder composition. Inhaler 400 comprises also an administration unit 411. The administration unit 411 is provided with a mixing chamber and airflow channels. Administration unit 411 is controlled by the loading handle 412, pulling the handle 412 releases the dose of a dry powder pharmaceutical composition into the mixing chamber of the administration unit 411. When the dose of the dry powder pharmaceutical composition is in the mixing chamber, the inhaler 400 is ready to use by the patient.

[0234] FIG. 18 shows the inhaler 400 according to the invention provided with a control module comprising a communication means 401, control means 402, blocking means 403, memory 404, and preferably a measurement unit 405.

[0235] FIG. 18 shows the inhaler 400 in the closed configuration suitable for storage or transportation. In this configuration the inhaler 400 does not allow administration of the pharmaceutical composition. In order to open the inhaler 400 into the open configuration, the storage 410 and administration unit 411 need to be rotated out of the control module. In the closed configuration the administration unit 411 is covered by the control module that blocks access to the administration unit 411. Rotating the storage 410 and administration unit 411 out of the control module, exposes administration unit 411 to the patient. In the closed configuration the blocking means 403 objects to the rotation of the storage 410 with administration unit 411. The blocking means 403 in the form of a bolt is extending into a channel in which the handle 412 travels when the storage 410 and administration unit 411 are rotated during the conversion of the inhaler 400 from the closed configuration into the open configuration. The blocking means 403 effectively blocks the turn of the storage 410 and administration unit 411 in this way blocking means 403 does not allow the inhaler to be converted into the open configuration thus, does not allow to administer the pharmaceutical composition.

[0236] The control module of the inhaler 400 comprises communication means 401, control means 402, blocking means 403, memory 404, and preferably a measurement unit 405. The power source and drive unit for actuating the blocking means (not depicted) are also within the control module.

[0237] The control means 402 of the inhaler 400 processes the administration scheme 11 in response to registration in the inhaler 400 of the authorisation token 12 assigned to the patient's mobile device 300, while the controlled blocking means 403 allows administration of the dry powder pharmaceutical composition only with compliance with the administration scheme 11 in the presence of a patient's mobile device 300 with the authorisation token 12 asssigned thereto.

[0238] Registration of the authorisation token 12 assigned to the inhaler 300 means transferring the authorisation token 12 assigned to the patient's mobile device 300 into the memory 404 of the inhaler 400. Alternatively, the inhaler 400 registers a confirmation that the authorisation token 12 has been assigned to the patient's mobile device 300. This can be done via the communications means 401 establishing a communication channel between the inhaler 400 and the mobile device 300. Preferably the communication channel is a near field or close range communication channel or the communication channel enables the distance measurement between the mobile device 300 and the inhaler 400, for example NFC or Bluetooth.

[0239] The administration scheme 11 in this embodiment is pre-stored in the memory 404 of the inhaler 400. However, it can be transmitted along with the authorisation token 12 and then stored in the memory 404 of the inhaler 400.

[0240] The control means 402 provided with administration scheme 11 determines the time slots when the inhaler 400 can be converted from the closed configuration into the open configuration. As the second level of protection against abuse and misuse of the pharmaceutical composition in this case esketamine, the control unit 402 checks if a patient's mobile device 300 with the authorisation token 12 assigned thereto is present near the inhaler 400.

[0241] Therefore, the inhaler 400 cross-checks the presence of the mobile device 300 with the authorisation token 12 assigned thereto, in the proximity of the inhaler 400. This is done by using a close range communication means. The Lack of communication connection between the inhaler 400 and the mobile device 300 is understood as being out of range position of the two, hence, the distance between the two devices is larger than expected.

[0242] Having the two conditions fullfield at the same time the control unit 402 is providing a control signal to the drive unit to withdraw the blocking means 403 from the channel in which the handle 412 travels, allowing this way to convert the inhaler 400 from the closed configuration into the open configuration.

[0243] Having in place the system 1 for electronically supervised administration of a pharmaceutical composition a method for treatment of depression in a patient in need thereof, one can implement the method comprising self-administration of ketamine or its pharmaceutically acceptable salt by said patient by pulmonary route as dry powder inhalable pharmaceutical formulation via an inhaler 400 in a remotely dictated and controlled manner in accordance with an administration scheme 11 prescribed by the attending physician, in the presence of a patient's mobile device 300 with the authorisation token 12 assigned thereto. In the method according to the invention said inhaler 400 is operated in compliance with the administration scheme 11 via a controlled blocking means 403 adapted to allow administration of a pharmaceutical composition only with compliance with the administration scheme 11 in the presence of a patient's mobile device 300 with the authorisation token 12 assigned thereto. The inhaler 400 may comprise ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression, wherein ketamine or its pharmaceutically acceptable salt is administered by the pulmonary route as a dry powder pharmaceutical composition. The pharmaceutically acceptable salt may be hydrochloride. The ketamine may be esketamine hydrochloride.

[0244] The composition may comprise from 2 mg to 100 mg of micronized ketamine calculated as a free base per nominal unit dose. The composition may comprise from 2 mg to 40 mg of micronized ketamine calculated as a free base per nominal unit dose. The composition may comprise 4 mg of micronized esketamine calculated as a free base per nominal unit dose. The composition may comprise one or more additives selected from the group consisting of a carbohydrate bulking agent in the amount of 30 to 95% by weight and a stabilizing agent in the amount of 0.2 - 3% by weight, with respect to the total weight of the composition. The composition may comprise ketamine having median particle diameter d50 of 1 - 10 μm, d10 of 0.2 - 5 μm and d90 of 3 - 35 μm, as measured by laser diffraction technique. The inhaler may be adapted to provide emitted dose of at least 1.0 mg of ketamine calculated as a free base, corresponding to 1.2 mg of ketamine hydrochloride. The fraction 5 of the emitted dose delivered to the lungs may be at least 40%.

[0245] The composition for administration via pulmonary route may be comprised in a blister with a plurality of individual nominal unit doses premetered and individually sealed. The composition for administration via pulmonary route may be comprised in a capsule with a single nominal unit dose. The composition for administration via pulmonary route may be comprised in a multi-dose powder reservoir.

[0246] The administration scheme 11 may provide a self-administration by a patient by inhalation of a dry powder ketamine composition or formulation in a sequence of administrations consisting of multiple single doses, for example such as a sequence of at least 3 single doses, each single dose consisting of multiple puffs, such as 1, 2, 3 or 4 puffs, preferably 3 or 4 puffs, said sequences being separated from each other by a break period without any inhalation. The administration scheme 11 may comprise the sequence of esketamine three single doses consisting of 3 or 4 puffs in a period of 30 minutes, single doses being separated by a break periods of 15 minutes, wherein each puff corresponds to esketamine nominal dose of 4 mg in the dry powder composition or formulation.